Sign up
Log in
BUZZ-U.S. STOCKS ON THE MOVE-Revance Therapeutics, B Riley Financial, KeyCorp
Share
Listen to the news
BUZZ-U.S. STOCKS ON THE MOVE-Revance Therapeutics, B Riley Financial, KeyCorp

Eikon search string for individual stock moves: STXBZ

The Day Ahead : https://refini.tv/3LI4BU7

The Morning News Call : https://refini.tv/3dKUyB8

Wall Street was set for a higher open on Monday as indexes add to their recovery from a hammering early last week, with investors gearing up for a deluge of data including U.S. consumer prices. .N


At 9:06 ET, Dow e-minis 1YMc1 were up 0.12% at 39,688. S&P 500 e-minis ESc1 were up 0.21% at 5,381.5, while Nasdaq 100 e-minis NQc1 were up 0.25% at 18,661.75.

The top three NYSE percentage gainers premarket .PRPG.NQ:
** Keycorp , up 17.7%
** Allurion Technologies , up 11.4%
** Banco Santander-Chile , up 9.6%

The top NYSE percentage loser premarket .PRPL.NQ:
** Infintt Acquisition , down 17.9%

The top two Nasdaq percentage gainers premarket .PRPG.O:
** Greenlane Holdings , up 275.6%
** Interactive Strength , up 124.8%

** Humacyte Inc HUMA.O: down 8.3% premarket
BUZZ - Falls after US FDA extends review of co's blood vessel implant


** Starbucks Corp SBUX.O: up 2.5% premarket
BUZZ - Gains after report Starboard Value takes stake


** Hawaiian Electric Industries Inc HE.N: down 14.5% premarket
BUZZ - Falls after raising going concern doubts


** KeyCorp KEY.N: up 17.7% premarket
BUZZ - Scotiabank to buy minority stake in KeyCorp, shares rise


** Barrick Gold Corp GOLD.N: up 3.1% premarket
BUZZ - Rises after upbeat second-quarter profit


** B Riley Financial Inc RILY.O: down 47.8% premarket
BUZZ - Plunges after prelim Q2 results, media reports of expanding US probe


** JetBlue Airways Corp JBLU.O: down 9.9% premarket
BUZZ - Falls after announcement of convertible offering


** Ascendis Pharma A/S ASND.O: up 10.1% premarket
BUZZ - Rises after U.S. FDA approves its hormone disorder therapy


** Revance Therapeutics Inc RVNC.O: up 85.8% premarket
BUZZ - Surges on buyout by Crown Laboratories in $924 mln deal


(Compiled by Rajarshi Roy and Anshuman Tripathy)

((Rajarshi.Roy@thomsonreuters.com))

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.